Test Price
1,400 AED✅ Home Collection Available
ALK/EML4 (NSCLC) Gene Rearrangement Test in UAE | 1400 AED | 2026 DHA Guidelines
تحليل إعادة ترتيب جين ALK/EML4 لسرطان الرئة غير صغير الخلايا في الإمارات | 1400 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by qualified oncology liaison personnel.
- ✓ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
ملخص تنفيذي
يُعد تحليل إعادة ترتيب جين ALK/EML4 فحصاً جزيئياً دقيقاً يُجرى على أنسجة الورم باستخدام تقنية التهجين الموضعي المتألق (FISH)، وهو معتمد وفق المعايير الدولية ISO 9001:2015. يضمن هذا الفحص دقة تشخيصية تصل إلى 99.9%، وتُقدَّم خدمة سحب العينات منزلياً عبر فريق تمريضي متخصص مع الالتزام بسلسلة التبريد المعتمدة. يتوفر دعم طبي هاتفي بعد صدور النتائج لتفسيرها سريرياً، إلى جانب خدمة التحقق المباشر من التأمين الصحي عبر تطبيق واتساب.
Overview
The ALK/EML4 gene rearrangement test is a definitive molecular diagnostic assay that detects oncogenic fusion events in anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) genes within tumor tissue, guiding targeted therapy eligibility for non-small cell lung carcinoma (NSCLC) patients. يكتشف هذا التحليل الطفرات الجينية الاندماجية في جيني ALK وEML4 داخل نسيج الورم الرئوي.
| Feature | Our Test (FISH) | IHC Screening | NGS Panel |
|---|---|---|---|
| Methodology | Fluorescence In-Situ Hybridization (FISH) — Gold Standard | Immunohistochemistry (IHC) | Next-Generation Sequencing (NGS) |
| Diagnostic Sensitivity | 99.9% | ~85–90% | ~99% |
| Turnaround Time (TAT) | 4–5 Days | 2–3 Days | 10–14 Days |
| Clinical Utility | Confirmatory — Directs ALK Inhibitor Therapy | Preliminary Screening Only | Broad Genomic Profiling |
| Price | 1,400 AED | ~800 AED | ~3,500+ AED |
Physician Insight & Safety Protocol
Clinical Perspective from Dr. PRABHAKAR REDDY (DHA License: 61713011):
"As a clinician, I remind every patient that an ALK rearrangement test result must always be interpreted within the full context of your histopathology report, imaging studies, and clinical stage. A positive FISH finding opens the door to highly effective ALK-targeted therapies, but treatment decisions require a comprehensive multidisciplinary tumor board review. I urge you never to view this molecular result in isolation—your oncologist will integrate it with all available data to craft the most effective, personalized care plan for your NSCLC journey."
⚠ Medication Warning:
Do not discontinue any prescribed medication without consulting your treating physician. This test is a diagnostic assessment and does not replace ongoing therapeutic management. Abrupt cessation of prescribed oncology medications, corticosteroids, or supportive care drugs may precipitate serious adverse events.
⚠ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria:
- Inadequate or necrotic tumor tissue specimen (insufficient viable cells for FISH analysis).
- Specimen not collected in an approved sterile container or transported outside cold-chain parameters.
- Patients under 18 years of age without valid guardian consent as per CDS Law 2026 (Minors).
- Non-NSCLC tumor types — this assay is validated specifically for non-small cell lung carcinoma tissue.
Emergency Red Flags — Seek Immediate Medical Attention:
- Acute onset of severe dyspnea, hemoptysis, or chest pain — proceed to the nearest Emergency Department.
- Signs of superior vena cava syndrome (facial swelling, distended neck veins, stridor).
- New neurological deficits, seizures, or altered mental status in the context of known NSCLC.
- Uncontrolled febrile neutropenia or signs of sepsis in immunocompromised oncology patients.
Patient FAQ & Clinical Guidance
Q1: What is the ALK/EML4 gene rearrangement test and why is it critical for NSCLC management?
The ALK/EML4 gene rearrangement test is a precision molecular diagnostic assay that detects abnormal fusion genes in non-small cell lung cancer tumor tissue using Fluorescence In-Situ Hybridization technology. This fusion drives oncogenic signaling, and its identification is essential because patients harboring ALK rearrangements demonstrate remarkable responses to targeted ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, alectinib, ceritinib, brigatinib, and lorlatinib. Without this test, eligible patients may miss the opportunity for highly effective, less toxic targeted therapy and instead receive conventional chemotherapy with inferior outcomes.
يكتشف اختبار إعادة ترتيب جين ALK/EML4 الطفرات الاندماجية في نسيج ورم الرئة، وهو ضروري لتحديد الأهلية للعلاج الموجه بمثبطات ALK.
Q2: How is the ALK/EML4 test performed and what preparation is required?
The ALK/EML4 FISH test is performed on formalin-fixed paraffin-embedded tumor tissue obtained through biopsy or surgical resection, and no specific fasting or dietary preparation is required from the patient. A valid doctor's prescription is mandatory for this test, except in cases of emergency surgery, confirmed pregnancy, or for individuals with documented international travel plans. Our VIP Mobile Phlebotomy team can coordinate specimen collection and transport under ISO-certified cold-chain conditions. The test requires only the existing tumor tissue block or slides — no additional invasive procedure is needed if adequate archival tissue is available.
يُجرى الفحص على عينة نسيجية من الورم محفوظة بالفورمالين ومغمورة بالبرافين، ولا يتطلب أي تحضيرات خاصة من المريض كالصيام.
Q3: What does a positive ALK/EML4 result mean for my treatment options and prognosis?
A positive ALK/EML4 rearrangement result indicates eligibility for targeted ALK inhibitor therapy such as crizotinib, alectinib, or lorlatinib, which significantly improves progression-free survival and overall response rates in advanced NSCLC patients. Modern ALK inhibitors have transformed ALK-positive NSCLC from an aggressive subtype into a chronically manageable condition with median progression-free survival exceeding 34 months on front-line next-generation agents. Your oncologist will use this result alongside staging and performance status to select the optimal first-line ALK TKI and sequence subsequent therapies should resistance emerge.
تشير النتيجة الإيجابية إلى أهلية المريض لتلقي مثبطات ALK الموجهة، مما يُحسن بشكل كبير من معدلات البقاء على قيد الحياة دون تطور المرض.
Regulatory Compliance: This laboratory service operates in full accordance with Federal Decree-Law No. 41 of 2024 (Article 87), CDS Law 2026 (Minors), and the UAE Personal Data Protection Law (PDPL). Patient data privacy and informed consent protocols are strictly enforced.
Accreditation: ISO 9001:2015 Certified — Cert: INT/EGQ/2509DA/3139. Facility License: 9834453.
Pre- Requirement: A valid Doctor's prescription is required. Prescription requirement is waived only for confirmed surgery cases, pregnancy cases, or individuals with documented international travel plans.
Sample Type: Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block or Unstained Slides. TAT: 4–5 Working Days. Methodology: Fluorescence In-Situ Hybridization (FISH).
Contact: WhatsApp Support at +971 54 548 8731 | Home Collection Available: 8 AM – 11 PM Daily.
جميع الخدمات معتمدة من هيئة الصحة بدبي وتلتزم بالقوانين الاتحادية لدولة الإمارات العربية المتحدة.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians